title: Effects of silodosin and tamsulosin on the urethra and cardiovascular system in young and old dogs with benign prostatic hyperplasia.
abstract: We examined whether the effects (efficacy on the urethra and hypotension) of silodosin (alpha(1A)-adrenoceptor antagonist) and tamsulosin (alpha(1A+1D)-adrenoceptor antagonist) in dogs with benign prostatic hyperplasia altered with age. We used young and old dogs, diagnosed as having benign prostatic hyperplasia by veterinarian's palpation. Under anesthesia, the increase in intraurethral pressure evoked by hypogastric nerve stimulation was measured, together with the level of systemic mean blood pressure. Each drug was administered intravenously in progressively increasing doses. At the end of the experiment, the prostate was isolated from each dog, then weighed and investigated pathologically to confirm benign prostatic hyperplasia. The wet weight of the prostate was greater in old dogs with benign prostatic hyperplasia than in young dogs with benign prostatic hyperplasia. By light microscopy, hyperplasia in the prostatic epithelium was confirmed in both groups. Silodosin (0.3-300 microg/kg) dose-dependently inhibited the hypogastric nerve stimulation-induced increase in intraurethral pressure (without significant hypotensive effects) in both young and old dogs with benign prostatic hyperplasia. Tamsulosin (0.3-300 microg/kg) also dose-dependently inhibited the intraurethral pressure increase in both groups, but it had a hypotensive effect that was significantly greater in old than in young dogs with benign prostatic hyperplasia. In conclusion, as regards the effect of silodosin on intraurethral pressure, potency was similar between young and old dogs with benign prostatic hyperplasia, and it was without significant hypotensive effects. We therefore suggest that silodosin might be a good medication for lower urinary tract symptoms in patients with benign prostatic hyperplasia in all age groups.
authors.affiliation: Pharmacology Research and Development, Kissei Pharmaceutical Co Ltd, Nagano, Japan. shinya_kobayashi@pharm.kissei.co.jp
authors.forename: Shinya
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Tomiyama
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tatemichi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hoyano
authors.forename: Mamoru
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Yamazaki
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000375:Aging; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects* / Q000503:physiopathology; D004285:Dogs; D006339:Heart Rate / Q000187:drug effects; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011312:Pressure; D011467:Prostate / Q000187:drug effects / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000473:pathology / Q000503:physiopathology*; D013449:Sulfonamides / Q000494:pharmacology*; D000077409:Tamsulosin; D014521:Urethra / Q000187:drug effects* / Q000503:physiopathology
chemical_list: D000317:Adrenergic alpha-Antagonists; D007211:Indoles; D013449:Sulfonamides; C095285:silodosin; D000077409:Tamsulosin